- Home
- ACB vs DSGN Comparison
ACB vs DSGN Comparison
Compare ACB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- DSGN
- Stock Information
- Founded
- ACB 2013
- DSGN 2017
- Country
- ACB Canada
- DSGN United States
- Employees
- ACB N/A
- DSGN N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- DSGN Health Care
- Exchange
- ACB Nasdaq
- DSGN Nasdaq
- Market Cap
- ACB 256.5M
- DSGN 208.9M
- IPO Year
- ACB N/A
- DSGN 2021
- Fundamental
- Price
- ACB $5.27
- DSGN $5.77
- Analyst Decision
- ACB
- DSGN
- Analyst Count
- ACB 0
- DSGN 0
- Target Price
- ACB N/A
- DSGN N/A
- AVG Volume (30 Days)
- ACB 2.5M
- DSGN 198.4K
- Earning Date
- ACB 11-05-2025
- DSGN 11-07-2025
- Dividend Yield
- ACB N/A
- DSGN N/A
- EPS Growth
- ACB N/A
- DSGN N/A
- EPS
- ACB N/A
- DSGN N/A
- Revenue
- ACB $262,403,032.00
- DSGN N/A
- Revenue This Year
- ACB $9.42
- DSGN N/A
- Revenue Next Year
- ACB $5.72
- DSGN N/A
- P/E Ratio
- ACB N/A
- DSGN N/A
- Revenue Growth
- ACB 28.58
- DSGN N/A
- 52 Week Low
- ACB $3.42
- DSGN $2.60
- 52 Week High
- ACB $6.91
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ACB 48.14
- DSGN 45.10
- Support Level
- ACB $4.90
- DSGN $5.28
- Resistance Level
- ACB $5.40
- DSGN $7.21
- Average True Range (ATR)
- ACB 0.37
- DSGN 0.49
- MACD
- ACB -0.08
- DSGN -0.14
- Stochastic Oscillator
- ACB 21.25
- DSGN 25.26
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.